Relevant bibliographies by topics / BRCA 2

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'BRCA 2'

Author: Grafiati
Published: 2 June 2025
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'BRCA 2.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "BRCA 2"

1

Richters, Lisa Katharina, Philip C. Schouten, Stefan Kommoss, et al. "BRCA-like classification in ovarian cancer: Results from the AGO-TR1-trial." Journal of Clinical Oncology 35, no. 15_suppl (2017): 5546. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.5546.

Full text
Abstract:
5546 Background: BRCA associated cancers show a distinct pattern of genomic gains and losses that is associated with impaired repair of DNA double-strand breaks via homologous recombination (HR). We investigated whether BRCA1- and BRCA2-like classifiers could predict BRCA1 and BRCA2 mutation status in ovarian cancer. In addition, we explored whether promoter hypermethylation or mutations in other genes involved in DNA repair associate with a BRCA-like profile in ovarian cancer. Methods: The AGO-TR1 cohort study (NCT02222883 ) enrolled 525 consecutive patients with primary (PR) and platinum sen
APA, Harvard, Vancouver, ISO, and other styles
2

Incorvaia, Lorena, Chiara Brando, Alessandro Perez, et al. "Real life use of biomarkers of homologous recombination deficiency (HRD) status beyond BRCA to predict the effectiveness of PARP inhibitors in ovarian cancer patients." Journal of Clinical Oncology 41, no. 16_suppl (2023): 10592. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.10592.

Full text
Abstract:
10592 Background: Testing for BRCA mutations (BRCAm) and genomic instability can identify epithelial ovarian cancer (OC) patients most likely to benefit from PARP-inhibitors (PARPi). However, current biomarkers of non- BRCA Homologous Recombination Repair (HRR) mutations are insufficient for guiding use of PARPi in the clinic. Despite non- BRCA HRR pathway gene mutations are rare, these patients may benefit from PARPi. Furthermore, recent preclinical findings showed that sensitivity to PARPi could be associated also with mutations in mismatch repair (MMR) genes, although sensitivity in the cli
APA, Harvard, Vancouver, ISO, and other styles
3

Foglietta, Jennifer, Vienna Ludovini, Fortunato Bianconi, et al. "Prevalence and Spectrum of BRCA Germline Variants in Central Italian High Risk or Familial Breast/Ovarian Cancer Patients: A Monocentric Study." Genes 11, no. 8 (2020): 925. http://dx.doi.org/10.3390/genes11080925.

Full text
Abstract:
Hereditary breast and ovarian cancers are mainly linked to variants in BRCA1/2 genes. Recently, data has shown that identification of BRCA variants has an immediate impact not only in cancer prevention but also in targeted therapeutic approaches. This prospective observational study characterized the overall germline BRCA variant and variant of uncertain significance (VUS) frequency and spectrum in individuals affected by breast (BC) or ovarian cancer (OC) and in healthy individuals at risk by sequencing the entire BRCA genes. Of the 363 probands analyzed, 50 (13.8%) were BRCA1/2 mutated, 28 (
APA, Harvard, Vancouver, ISO, and other styles
4

Murciano-Goroff, Yonina R., Alison M. Schram, Ezra Rosen, et al. "BRCA reversion mutations in a pan-cancer cohort to reveal BRCA-dependence in select noncanonical BRCA-mutant histologies." Journal of Clinical Oncology 39, no. 15_suppl (2021): 3012. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.3012.

Full text
Abstract:
3012 Background: Loss of BRCA1/2 function leads to homologous recombination deficiency (HRD) and can enhance platinum and PARP inhibitor sensitivity in breast, pancreas, prostate, and ovarian cancers. In BRCA-associated cancers, resistance can result from the development of BRCA1/2 reversion mutations, which restore BRCA1/2 function. By contrast, a BRCA mutation may be an incidental finding in other tumor histologies. Methods: To determine the distribution of reversion mutations in a pan-cancer cohort, the MSK-IMPACT clinical sequencing cohort was mined to identify patients who had both a germ
APA, Harvard, Vancouver, ISO, and other styles
5

Sandoval, Jose, Marie Charlotte Villy, Intidhar Labidi-Galy, et al. "Genomic instability score (GIS) and benefit from olaparib (ola) and bevacizumab (bev) maintenance in high-grade ovarian cancer (HGOC): Phase III PAOLA-1 GINECO/ENGOT-ov25 trial exploratory analysis." Journal of Clinical Oncology 43, no. 16_suppl (2025): 5576. https://doi.org/10.1200/jco.2025.43.16_suppl.5576.

Full text
Abstract:
5576 Background: The PAOLA-1 trial showed that adding ola to bev as maintenance therapy improved overall survival (OS) of HGOC patients with BRCA1/2 mutations (BRCAm) or homologous recombination (HR) deficiency (HRD) defined by the MyChoice HRD Plus assay with a GIS threshold of 42. This post hoc analysis of PAOLA-1 explored if alternative thresholds could better identify patients who benefit most from ola. Methods: New cutoffs were determined through OS analyses using Cox proportional hazards models with an interaction term for GIS. Tumors were categorized into HRP (GIS<42), HRDlow (42–60
APA, Harvard, Vancouver, ISO, and other styles
6

Sekine, Masayuki, Koji Nishino, and Takayuki Enomoto. "Differences in Ovarian and Other Cancers Risks by Population and BRCA Mutation Location." Genes 12, no. 7 (2021): 1050. http://dx.doi.org/10.3390/genes12071050.

Full text
Abstract:
Hereditary breast and ovarian cancer is caused by a germline mutation in BRCA1 or BRCA2 genes. The frequency of germline BRCA1/2 gene mutation carriers and the ratio of germline BRCA1 to BRCA2 mutations in BRCA-related cancer patients vary depending on the population. Genotype and phenotype correlations have been reported in BRCA mutant families, however, the correlations are rarely used for individual risk assessment and management. BRCA genetic testing has become a companion diagnostic for PARP inhibitors, and the number of families with germline BRCA mutation identified is growing rapidly.
APA, Harvard, Vancouver, ISO, and other styles
7

Schwartz, Zachary Phillip, Mae Zakhour, Andrew John Li, et al. "Comparison of risk-reducing surgery in women with BRCA and non-BRCA ovarian cancer susceptibility genes." Journal of Clinical Oncology 37, no. 15_suppl (2019): 1547. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.1547.

Full text
Abstract:
1547 Background: Risk reducing gynecologic surgery (RRSO) is standard of care for women with BRCA mutations. The optimal management for women with non-BRCA ovarian cancer susceptibility mutations remains unclear. We sought to characterize the practice patterns for these women at our two institutions. Methods: Women with germline ovarian cancer susceptibility genes who had a RRSO were identified from 1/2000-1/2019 in an IRB approved study. All patients were asymptomatic with no suspicion for malignancy at time of RRSO. Clinico-pathologic characteristics were extracted from the medical records.
APA, Harvard, Vancouver, ISO, and other styles
8

Meireles, Pedro Antunes, Catarina Bexiga, Sofia Fragoso, Sidónia Santos, Teresa Duarte, and Fátima Vaz. "Abstract PO3-08-03: Comparing prognosis for BRCA1, BRCA2 and non-BRCA breast cancer." Cancer Research 84, no. 9_Supplement (2024): PO3–08–03—PO3–08–03. http://dx.doi.org/10.1158/1538-7445.sabcs23-po3-08-03.

Full text
Abstract:
Abstract BACKGROUND Breast Cancer (BC) is the most diagnosed malignancy and the leading cause of cancer death in women worldwide. Approximately 10% of BC cases are hereditary, and up to 25% have been linked to germline variants of specific genes. Germline pathogenic variants (PV) in BRCA1 and BRCA2 genes, which account for 20% of familial BC cases, are highly penetrant and are associated with Hereditary Breast/Ovarian Cancer Syndrome. BRCA1 e BRCA2 are tumor suppressor genes, which interact with recombination/DNA repair proteins in pathways that participate in preserving intact chromosome stru
APA, Harvard, Vancouver, ISO, and other styles
9

Miller, Robert S., Stella Mokiou, Aliki Taylor, Ping Sun, and Katherine Baria. "Real-world clinical outcomes of patients with BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: a CancerLinQ® study." Breast Cancer Research and Treatment 193, no. 1 (2022): 83–94. http://dx.doi.org/10.1007/s10549-022-06541-3.

Full text
Abstract:
Abstract Purpose To investigate real-world clinical outcomes in patients with BRCA-mutated (BRCAm), HER2-negative metastatic breast cancer (mBC) according to BRCA and hormone receptor (HR) status. Methods Patients diagnosed with HER2-negative mBC between 01 January 2010 and 31 December 2018 were retrospectively identified from the American Society of Clinical Oncology’s CancerLinQ Discovery® database. Time to first subsequent therapy or death (TFST) from date of mBC diagnosis and start of first-line treatment for mBC and overall survival (OS) from date of mBC diagnosis were investigated accord
APA, Harvard, Vancouver, ISO, and other styles
10

Seeber, Andreas, Kai Zimmer, Florian Kocher, et al. "Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma." ESMO Open 5, no. 6 (2020): e000942. http://dx.doi.org/10.1136/esmoopen-2020-000942.

Full text
Abstract:
IntroductionPoly-(ADP)-ribose polymerase (PARP) inhibitors are successfully used for treatment of BRCA-mutated (mut) breast cancers and are under extensive evaluation for BRCA- and PALB2-mutated pancreatic ductal adenocarcinoma (PDAC). However, the optimal treatment regimen for BRCA/PALB2-mutated PDCA has yet to be established. Moreover, limited data are available on the association of BRCA/PALB2 gene alterations with other comutations and immunological biomarkers.Material and methodsTumour samples of 2818 patients with PDAC were analysed for BRCA1/2 PALB2 mutations and other genes by next-gen
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "BRCA 2"

1

Song, Yun. "CNS Metastasis Patterns in BRCA1/2 Mutation Associated and Non-BRCA Associated Breast Cancers." Thesis, Harvard University, 2015. http://nrs.harvard.edu/urn-3:HUL.InstRepos:17295883.

Full text
Abstract:
BRCA1 and BRCA2 germline mutations give rise to phenotypically distinct breast cancers (BC): triple negative (TNBC) and hormone positive, respectively. Different BC subtypes are associated with different patterns of metastasis, including propensity for central nervous system (CNS) metastasis. Purpose of this study is to compare BC recurrence patterns and CNS metastasis rate by BRCA mutation status. This retrospective study included 332 women with confirmed BRCA mutation (30 BRCA1, 32 BRCA2, 270 negative) and diagnosed with locally recurrent or metastatic BC. BRCA1 carriers often metastasized
APA, Harvard, Vancouver, ISO, and other styles
2

Palfner, Sonja. "Gen-Passagen molekularbiologische und medizinische Praktiken im Umgang mit Brustkrebs-Genen ; Wissen - Technologie - Diagnostik." Bielefeld Transcript, 2008. http://d-nb.info/994330804/04.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Ginolhac, Sophie. "Facteurs génétiques modificateurs du risque de cancer du sein et de l'ovaire chez les femmes porteuses d'une mutation constitutionnelle des gènes BRCA1 ou BRCA 2." Lyon 1, 2003. http://www.theses.fr/2003LYO1T149.

Full text
Abstract:
La 4e de couverture indique : "Les porteuses de mutations germinales des gènes BRCA1 et BRCA2 ont un risque élevé de développer un cancer du sein et également de l'ovaire. Cependant, il existe une grande variabilité du risque tumoral chez ces porteuses qui dépend du gène en cause, de différents facteurs environnementaux, physiologiques et hormonaux mais probablement aussi de facteurs génétiques. Notre étude a eu pour objectif d'identifier certains de ces facteurs génétiques modificateurs afin d'améliorer l'évaluation du risque cancéreux individuel des porteuses de mutation BRCA et donc leur pr
APA, Harvard, Vancouver, ISO, and other styles
4

Reilly, Drew D. "The Narratives of Young Women with BRCA 1/2 Gene Mutation: A Qualitative Analysis." ScholarWorks@UNO, 2014. http://scholarworks.uno.edu/td/1910.

Full text
Abstract:
A narrative qualitative research design was used to understand the stories of young women diagnosed with BRCA1 and BRCA 2 genetic mutation. Four participants were selected who met the following criteria: (a) the participant is diagnosed with BRCA1 or BRCA2 genetic mutation, b) is within the age range of 18 to 35, (c) is without a cancer diagnosis, and is (d) not currently pregnant and does not have children. The four participants were interviewed through open-ended inquiry. The participants’ narratives proved both similar and dissimilar. The themes were organized into within-case narratives an
APA, Harvard, Vancouver, ISO, and other styles
5

Jansson, Sandra, and Lisa Candell. "Ett liv i förändring - att bära på mutation i BRCA 1- eller BRCA 2-genen: en skildring av kvinnors upplevelser : En litteraturöversikt." Thesis, Uppsala universitet, Institutionen för folkhälso- och vårdvetenskap, 2019. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-396781.

Full text
Abstract:
Bakgrund: Mutation i BRCA-generna innebär kraftigt ökad risk att utveckla bröst- och ovarialcancer. Vetskap om att bära på denna genmutation innebär påfrestningar och psykosociala förändringar hos individen. Sjuksköterskor behöver insikt i hur detta tillstånd påverkar individen för att kunna tillfredsställa vårdbehovet på ett personcentrerat sätt. Syfte: Skildra kvinnors upplevelse av att bära på mutation i gen BRCA 1 eller BRCA 2. Metod: Allmän litteraturstudie med deskriptiv design. Resultatet baserades på tio originalartiklar med kvalitativ ansats från databaserna PubMed och Cinahl. Resulta
APA, Harvard, Vancouver, ISO, and other styles
6

Karlsson, Emelie, and Mitereme Saljii. "Kvinnors upplevelser av att leva med genmutation BRCA 1 och/eller BRCA 2 som ger ökad risk för bröst- och ovarialcancer." Thesis, Blekinge Tekniska Högskola, Institutionen för hälsa, 2020. http://urn.kb.se/resolve?urn=urn:nbn:se:bth-19100.

Full text
Abstract:
Bakgrund: Kvinnor som är bärare av BRCA 1 och/eller BRCA 2 löper en stor risk att drabbas av bröst- och ovarialcancer under sina unga år. Genmutationen är ingen sjukdom som syns med blotta ögat, trots det lämnar den de drabbade kvinnorna i situationer som är svåra att hantera själv. De ställs inför svåra beslut som rör både fysiska och psykiska aspekter. Därför behöver det undersökas vilka upplevelser kvinnorna har. På så sätt kan sjuksköterskor få en djupare förståelse kring ämnet som hjälper dem att kunna bemöta och vägleda dessa kvinnor på ett bättre sätt. Vilket går hand i hand med att kun
APA, Harvard, Vancouver, ISO, and other styles
7

Becker, Mikaela. "Women's Descriptions Six Months Post Notification of Positive BRCA 1/2 Genetic Mutations." Thesis, Capella University, 2017. http://pqdtopen.proquest.com/#viewpdf?dispub=10634312.

Full text
Abstract:
<p> A qualitative case study was used to analyze the experiences of 11 young women, ages 18&ndash;35 years diagnosed with breast cancer genetic mutations, BRCA 1 or BRCA 2. The 11 participants did not have a history or current diagnosis of breast or ovarian cancer. There was limited information available within the literature regarding the experiences of young women who have been notified of BRCA 1 and 2 genetic mutations. It seemed vital to understand how women confronted with the difficult reality of their genetic status would like professionals such as psychologists, physicians, and genetic
APA, Harvard, Vancouver, ISO, and other styles
8

Rudaitis, Vilius. "BRCA1/2 mutation spectrum and its prognostic significance for progression-free and overall survival in advanced ovarian cancer." Doctoral thesis, Lithuanian Academic Libraries Network (LABT), 2014. http://vddb.library.lt/obj/LT-eLABa-0001:E.02~2014~D_20140925_135101-34767.

Full text
Abstract:
In general population 1 of 72 women develop ovarian cancer and to 1 of 95 women this disease is lethal. A great number of clinical trials have shown that the course of the disease is not dependent only on the classical prognostic indicators such as histological tumor type, tumor differentiation, stage of the disease or treatment modalities. More than two decades ago the first publications on heredity factors indicated similarity among the patients diagnosed ovarian malignancies and their first degree relatives. The first genetic autosomal dominant inheritance was determined in the high-risk ca
APA, Harvard, Vancouver, ISO, and other styles
9

Lacy, Jessica. "Imaging of PARP1/2-Overexpressing Cancers with Novel AZD2281-Derived Probes." Thesis, Harvard University, 2014. http://etds.lib.harvard.edu/hms/admin/view/58.

Full text
Abstract:
Poly(ADP-ribose)polymerase-1 and -2 (PARP1/2) are nuclear proteins involved in DNA repair. Tumors with defects in homologous recombination, including BRCA1- and BRCA2-deficient cancers, have been shown to be sensitive to PARP inhibition. The Weissleder group has synthesized fluorescent and radioactive derivatives of the PARP1/2 inhibitor AZD2281. We hypothesized that fluorescent and radioactive AZD2281-based imaging agents would quantify PARP1/2 expression in vitro and in vivo. To test this hypothesis, a panel of pancreatic ductal adenocarcinoma and ovarian carcinoma cell lines were
APA, Harvard, Vancouver, ISO, and other styles
10

Rudaitis, Vilius. "Išplitusio kiaušidžių vėžio BRCA1/2 genų mutacijų įvairovė ir jų prognozinė reikšmė ligos berecidyviam ir bendrajam pacienčių išgyvenamumui." Doctoral thesis, Lithuanian Academic Libraries Network (LABT), 2014. http://vddb.library.lt/obj/LT-eLABa-0001:E.02~2014~D_20140925_135118-11686.

Full text
Abstract:
Bendrojoje populiacijoje 1 iš 72 moterų suserga kiaušidžių vėžiu ir 1 iš 95 moterų miršta nuo šios ligos. Tyrimų duomenys rodo, kad ligos eiga nėra priklausoma vien tik nuo klasikinių prognozinių rodiklių, tokių kaip histologinis naviko tipas, naviko diferenciacija, ligos stadija, taikytas gydymas.Prognozinių veiksnių paieška krypstą link genetinių veiksnių galinčių įtakoti ligos eigą. Literatūros duomenys apie klinikinę BRCA1/2 genų reikšmę yra kontroversiški – nuo visiškai bereikšmio iki ženkliai teigiamo poveikio ligos eigai prognoziniu požiūriu.. Mūsų tyrėjų grupės atlikto tyrimo tikslas
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "BRCA 2"

1

Herrlinger, Karolina Anna. Die Patentierung von Krankheitsgenen: Dargestellt am Beispiel der Patentierung der Brustkrebsgene BRCA 1 und BRCA 2. Heymanns, 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Zdeňka, Hladká, Karlík Petr, and Masarykova univerzita v. Brně, eds. Čeština--univerzália a specifika 2: Sborník konference ve Šlapanicích u Brna, 17.-19.11. 1999. Masarykova univerzita, 2000.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Dimitrijević, Braco. Brac o Dimitrijević: The man of Lascaux : Museum of Modern Art, 2.-26. April 1996. Museum of Modern Art, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Ulla, Elers, and Sweden Konsumentverket, eds. Recept på bra mat som inte är dyr: För 2 och 4 portioner. 3rd ed. Konsumentverket, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Jiřína, Hockeová, and Dům umění města Brna, eds. Sociální umění dvacátých let na Moravě: Výstava k 40. výročí Vítězného února : Dům umění města Brna, Malinovského nám. 2, Brno, 20. ledna-13. března 1988. Dům umění města Brna, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Istituto italiano di preistoria e protostoria. Riunione scientifica. Atti della XXXV Riunione scientifica: Le comunità della preistoria italiana : studi e ricerche sul neolitico e le età dei metalli : Castello di Lipari, Chiesa di S. Caterina, 2-7 giugno 2000 : in memoria di Luigi Bernabò Brea. [s.n.], 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

1943-, Jackson Frank, ed. The philosophy of mind and cognition. 2nd ed. Blackwell Pub., 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Breast Cancer Gene Research and Medical Practices: Transnational Perspectives in the Time of Brca. Routledge, 2014.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

GIBBON, SAHRA, Jessica Mozersky, Andrea zur Nieden, Galen Joseph, and Sonja Palfner. Breast Cancer Gene Research and Medical Practices: Transnational Perspectives in the Time of BRCA. Taylor & Francis Group, 2014.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

GIBBON, SAHRA, Jessica Mozersky, Andrea zur Nieden, Galen Joseph, and Sonja Palfner. Breast Cancer Gene Research and Medical Practices: Transnational Perspectives in the Time of BRCA. Taylor & Francis Group, 2014.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "BRCA 2"

1

O’Donoghue, Cristina, Sonia Orcutt, Tuya Pal, and Christine Laronga. "Risk-Reducing Surgery for BRCA1/2 Genetic Mutation Carriers." In Managing BRCA Mutation Carriers. Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-59198-8_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Devilee, Peter. "BRCA1/BRCA2 Germline Mutations and Breast Cancer Risk." In Encyclopedia of Cancer. Springer Berlin Heidelberg, 2015. http://dx.doi.org/10.1007/978-3-642-27841-9_713-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Markentein, L. F. "Hebben ouders het recht om een minderjarig kind te laten onderzoeken op het BRCA-1- of -2-gen?" In Vademecum permanente nascholing huisartsen. Bohn Stafleu van Loghum, 2006. http://dx.doi.org/10.1007/978-90-313-8808-0_751.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Rosen, Eliot M. "BRCA1 and 2." In Cancer Therapeutic Targets. Springer New York, 2017. http://dx.doi.org/10.1007/978-1-4419-0717-2_79.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Rosen, Eliot M. "BRCA1 and 2." In Cancer Therapeutic Targets. Springer New York, 2015. http://dx.doi.org/10.1007/978-1-4614-6613-0_79-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Greif, Michel. "Un territorio para el equipo." In La F brica Visual. Productivity Press, 2023. http://dx.doi.org/10.4324/9781003419891-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Wareham, Carly, and Salvatore Nardello. "Hereditary Breast Cancer (BRCA1/2)." In Passing the General Surgery Oral Board Exam. Springer Nature Switzerland, 2025. https://doi.org/10.1007/978-3-031-78244-2_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Lerman, Caryn, and Beth N. Peshkin. "Psychosocial Issues in BRCA1/2 Testing." In Breast Cancer. Humana Press, 1999. http://dx.doi.org/10.1007/978-1-59259-456-6_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Larson, Michael J. "Broca, Pierre Paul (1824–1880)." In Encyclopedia of Clinical Neuropsychology. Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-56782-2_604-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Canakci, Cengiz, and Erdinc Dincer. "Parp Inhibitors Therapy for Metastatic Prostate Cancer." In Current Management of Metastatic Prostate Cancer. Nobel Tip Kitabevleri, 2024. http://dx.doi.org/10.69860/nobel.9786053359142.11.

Full text
Abstract:
In this section, the success of targeted therapies that have proven effective in the last 20 years in metastatic prostate cancer is highlighted. Prostate cancer is one of the three most common cancers among men worldwide, and new treatment options are still being investigated. PARP (polyadenosine diphospate ribose polymerase) inhibitors might contribute clinical benefit in the treatment of homologous recombinant repair (HRR) alterations especially BRCA1/2 . The basis of its working mechanism is "synthetic lethality" and it is an effective treatment that has received FDA approval in the treatme
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "BRCA 2"

1

Farias, Stephanie Freire Soares de, Graziela Gama da Conceição Gomes, Biatriz Costa Diniz, CAIO DE BRITO MATOS, and MARCOS VINÍCIUS SOUZA DE ALMEIDA. "GENES RELACIONADOS AO CÂNCER DE MAMA: UM ESTUDO ACERCA DOS ONCOGENES." In I Congresso Nacional de Pesquisas e Estudos Genéticos On-line. Revista Multidisciplinar em Saúde, 2022. http://dx.doi.org/10.51161/geneticon/9136.

Full text
Abstract:
Introdução: O câncer de mama é uma patologia relacionada a mutações genéticas, como alterações patológicas em genes como: BRCA 1 e BRCA 2. De acordo com dados do Instituto Nacional do Câncer, no ano de 2022, é estimado 68.280 novos casos, número que representa uma incidência de 43,74 casos por 100 mil individuos do sexo feminino. Objetivo: entender a relação dos genes com o desenvolvimento do câncer de mama. Materiais e Métodos: foi realizado um levantamento bibliográfico nos bancos de dados online NCBI, Scielo e Lilacs, durante o mês de junho de 2022, utilizando as palavras-chaves, isoladas e
APA, Harvard, Vancouver, ISO, and other styles
2

Gomes, Marina Macedo, and Kamylle Cynnara Tavares da Silva. "MUTAÇÃO DOS GENES BRCA1 E BRCA2 COMO ETIOLOGIA GENÉTICA DO CÂNCER DE MAMA." In XXVII Semana de Biomedicina Inovação e Ciência. Editora IME, 2021. http://dx.doi.org/10.51161/9786588884119/8.

Full text
Abstract:
Introdução: Tendo em vista que mulheres portadoras de mutações em BRCA1 ou BRCA2 apresentam um risco de câncer de mama ao longo da vida de 50% a 85%,(5) as alterações herdadas desses genes se apresentam como considerável fator de risco para o desenvolvimento dessa categoria de câncer. Logo, a compreensão dessa correlação corresponde a um importante aspecto para o manejo de famílias de alto risco para câncer de mama. Objetivos: O presente trabalho apresenta como objetivo reunir informações relacionadas a presença de mutações nos genes BRCA1 e BRCA2 como etiologia genética do câncer de mama here
APA, Harvard, Vancouver, ISO, and other styles
3

Carvalho, Débora Medeiros de, Kamila Bezerra Fernandes Diocesano, Sabas Carlos Vieira, et al. "Epidemiological and histo-molecular profile of patients with breast cancer who underwent genetic testing at a tertiary clinic in northeastern Brazil." In Brazilian Breast Cancer Symposium 2023. Mastology, 2023. http://dx.doi.org/10.29289/259453942023v33s1069.

Full text
Abstract:
Objective: The aim of this study was to describe the epidemiological and histo-molecular profile of patients with breast cancer (CAM) who underwent genetic testing at an oncology clinic in northeastern Brazil. Methodology: This is a retrospective cohort study on patients with CAM who underwent genetic testing from 1998 to 2022 at a tertiary clinic in northeastern Brazil and who underwent multigene panel testing for hereditary cancer predisposition syndromes. Results: Data were collected from 208 patients, of which 122 had CAM. Of these, 14.75% were BRCA1, 11.47% were BRCA 2, 15.57% were VUS, 4
APA, Harvard, Vancouver, ISO, and other styles
4

Laura, A., MDLR Oliver, E. Felipe Pardo, et al. "1139 Ovarian cancer in brca 1 and brca 2 mutations carriers, clinicopathologycal features." In ESGO 2021 Congress. BMJ Publishing Group Ltd, 2021. http://dx.doi.org/10.1136/ijgc-2021-esgo.294.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Silva, Manuella Amlid Pimenta de Castro Cavalcanti, Caio Victor Barros Gonçalves da Silva, Dryelli Frances Santana da Silva, Laura Lucena Serafim, Ryan Cristian da Silva, and Celina Cavalcante Muniz Gomes. "A METILAÇÃO DO DNA COMO BIOMARCADOR NO PROGNÓSTICO E DIAGNÓSTICO DO CÂNCER OVARIANO: REVISÃO DE LITERATURA." In XXVII Semana de Biomedicina Inovação e Ciência. Editora IME, 2021. http://dx.doi.org/10.51161/9786588884119/2.

Full text
Abstract:
Introdução: O câncer ovariano é caracterizado pelo crescimento anormal de células provenientes dos ovários. Mutações no gene BRCA podem aumentar, entre 20 a 50%, o risco do paciente desenvolver câncer ovariano (1). Assim, o gene BRCA1 é expresso como autossômico dominante, com penetrância incompleta e atua como supressor de tumor, sendo importante para a reparação do DNA, pois atua na manutenção da estabilidade do genoma e no controle do ciclo celular no checkpoint (3). Desse modo, a metilação do DNA ocorre na região promotora do gene, local dos sítios CpG – sendo denominados assim pois um gru
APA, Harvard, Vancouver, ISO, and other styles
6

Schneider, V., E. Petru, J. Geigl, S. Jahn, K. Kashofer, and G. Pristauz. "Prospektiver Vergleich der Ergebnisse der Somatischen und Keimbahn-Testung im BRCA 1 und BRCA 2 Gen von Ovarialkarzinompatientinnen." In Jahrestagung der Österreichischen Gesellschaft für Gynäkologie und Geburtshilfe – OEGGG. Georg Thieme Verlag KG, 2018. http://dx.doi.org/10.1055/s-0038-1648300.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Schneider, V., E. Petru, C. Bracco, et al. "Prospektiver Vergleich der Ergebnisse der somatischen und Keimbahn-Testung im BRCA 1 und BRCA 2 Gen von Ovarialkarzinompatientinnen." In XXVII. Wissenschaftliche Tagung der Arbeitsgemeinschaft für Gynäkologische Onkologie (AGO) der Österreichischen Gesellschaft für Gynäkologie und Geburtshilfe (OEGGG) 2018. Georg Thieme Verlag KG, 2018. http://dx.doi.org/10.1055/s-0038-1635241.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Adam, Kindi, Holy Arif Wibowo, Rosa Adelina, et al. "BRCA 1 and BRCA 2 Gene Sequencing in Indonesian Urban Women: Further Study of Noncommunicable Disease Research 2016." In 4th International Symposium on Health Research (ISHR 2019). Atlantis Press, 2020. http://dx.doi.org/10.2991/ahsr.k.200215.109.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Felipe Pardo, E., MDLR Oliver, J. Montero Olmeda, et al. "756 Prophylactic salpingo-oophorectomy in BRCA 1–2 patients. Profile epidemiological." In ESGO 2021 Congress. BMJ Publishing Group Ltd, 2021. http://dx.doi.org/10.1136/ijgc-2021-esgo.555.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Cantor, Sharon B., and Nicholas Panzarino. "Abstract IA-026: Gaps alone kill BRCA deficient cancer cells." In Abstracts: AACR Virtual Special Conference on Radiation Science and Medicine; March 2-3, 2021. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1557-3265.radsci21-ia-026.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "BRCA 2"

1

Manne, Sharon. Impact of BRCA 1/2 Testing on Marital Relationships. Defense Technical Information Center, 1999. http://dx.doi.org/10.21236/ada368468.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Modugno, Francesmary. Ovarian Cancer Risk and Survival in BRCA 1/2 Carriers. Defense Technical Information Center, 2005. http://dx.doi.org/10.21236/ada444028.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Modugno, Francesmary. Ovarian Cancer Risk and Survival in BRCA 1/2 Carriers. Defense Technical Information Center, 2001. http://dx.doi.org/10.21236/ada406117.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Modugno, Francesmary. Ovarian Cancer Risk and Survival in BRCA 1/2 Carriers. Defense Technical Information Center, 2003. http://dx.doi.org/10.21236/ada420933.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Couch, Fergus J. Aurora-A as a Modifier of Breast Cancer Risk in BRCA 1/2 Mutation Carriers. Defense Technical Information Center, 2007. http://dx.doi.org/10.21236/ada473900.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Erblich, Joel, and Dana Bovbjerg. Psychological Distress, Cognitive Bias and Breast Cancer Surveillance Behavior in Women Tested for BRCA 1/2 Mutation. Defense Technical Information Center, 2001. http://dx.doi.org/10.21236/ada398143.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Erblich, Joel, and Dana H. Bovbjerg. Psychological Distress, Cognitive Bias and Breast Cancer Surveillance Behavior in Women Tested for BRCA 1/2 Mutation. Defense Technical Information Center, 2002. http://dx.doi.org/10.21236/ada409853.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Erblich, Joel, and Dana Bovbjerg. Psychological Distress, Cognitive Bias, and Breast Cancer Surveillance Behavior in Women Tested for BRCA 1/2 Mutation. Defense Technical Information Center, 2003. http://dx.doi.org/10.21236/ada420452.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Erblich, Joel, and Dana Bovbjerg. Psychological Distress, Cognitive Bias and Breast Cancer Surveillance Behavior in Women Tested for BRCA 1/2 Mutation. Defense Technical Information Center, 2000. http://dx.doi.org/10.21236/ada391104.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Olstad, Tyra, J. Beeco, J. Hutchinson, et al. Spatial patterns of overflights at Bryce Canyon National Park, updated 2023?2024. National Park Service, 2025. https://doi.org/10.36967/2307673.

Full text
Abstract:
This study explores spatial patterns of overflights at Bryce Canyon National Park (BRCA), using Automatic Dependent Surveillance-Broadcast (ADS-B) data collected between August 14, 2023 and September 03, 2024. It expands upon an earlier report using data collected only through March 2024, looking for potential changes to patterns during busy spring and summer seasons. The methodology remains largely the same. Phase 1 of analysis considered all overflights, finding commuter traffic following major flight paths dominates airspace near the park. Phase 2 focused on low-level overflights travelling
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'BRCA 2' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography